OrthoPediatrics Q2 2025 slides: Revenue up 16%, expanding specialty bracing market

OrthoPediatrics Corp (NASDAQ:KIDS) reported Q2 2025 revenue of $61.1 million, up 16% year-over-year, and improved adjusted EBITDA to $4.1 million, beating forecasts despite an increased operating loss of $10.6 million and a stock decline. The company raised its full-year 2025 revenue guidance to $237-242 million and targets positive free cash flow in 2025, supported by strategic acquisitions like Boston Orthotics & Prosthetics and ongoing product innovation in the pediatric orthopedic market. While gross margins compressed and the stock faces pressure, management is focused on leveraging market expansion and operational efficiency for future profitability.

Analysis

OrthoPediatrics Corp. (KIDS) presents a classic growth-versus-profitability dilemma for investors. The company reported strong Q2 2025 top-line performance with revenue increasing 16% year-over-year to $61.1 million, driven by a 17% rise in U.S. revenue and a 12% increase internationally. This performance prompted management to raise full-year 2025 revenue guidance to a range of $237-242 million, implying sustained 16-18% growth. Growth is being fueled by an aggressive expansion strategy, including a 12% CAGR in its U.S. sales force since 2016 and a 21% CAGR in its product portfolio over the same period. The recent $22 million acquisition of Boston Orthotics & Prosthetics opens a new $500 million U.S. specialty bracing market, a key future growth driver. However, this expansion is pressuring profitability. The operating loss widened significantly to $10.6 million from $5.7 million in the prior-year quarter, and gross profit margin compressed to 72% from 77%. Despite this, adjusted EBITDA improved to $4.1 million from $2.6 million, beating forecasts and supporting a full-year target of $15-17 million. The stock’s 1.66% decline post-earnings and its position near a 52-week low reflect market concern over the rising losses and cash burn, balanced against the company's dominant position in a $6.2 billion niche market and its clear roadmap toward a first-ever positive free cash flow quarter in 2025.

Key Decisions for Investors

• Investors focused on growth should analyze the company's ability to penetrate the new $500 million specialty bracing market as a primary catalyst, weighing it against the stock's -29.3% one-year return.
• It is critical to monitor the company's progress toward its stated goals of achieving its first positive free cash flow quarter in 2025 and hitting its full-year adjusted EBITDA forecast of $15-17 million, as failure to meet these targets would signal deeper operational issues.
• Value-oriented or risk-averse investors should exercise caution, focusing on the deteriorating gross margin, which fell to 72% from 77%, and the widening operating loss, which nearly doubled to $10.6 million year-over-year.
• Existing shareholders should assess the impact of the new product pipeline, particularly the recently FDA-approved VerteGlide system, on future revenue mix and margin profiles, as successful launches are necessary to justify the high R&D and expansion costs.